Sorafenib significantly improves the length of time before breast cancer worsens

Berlin, Germany: One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

Read the whole article on Physorg

More from Physorg